Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial

INTRODUCTION: Treatment with anti-PD-1 immunotherapy does not lead to long-lasting clinical responses in approximately 60% of patients with metastatic melanoma. These refractory patients, however, can still respond to treatment with tumour infiltrating lymphocytes (TIL) and interferon-alpha (IFNa)....

Descripción completa

Detalles Bibliográficos
Autores principales: van der Kooij, Monique K, Verdegaal, Els M E, Visser, Marten, de Bruin, Linda, van der Minne, Caroline E, Meij, Pauline M, Roozen, Inge C F M, Jonker, Mare A, van den Bosch, Shelley, Liefers, Gerrit-Jan, Speetjens, Frank M, van der Burg, Sjoerd H, Kapiteijn, Ellen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689077/
https://www.ncbi.nlm.nih.gov/pubmed/33234662
http://dx.doi.org/10.1136/bmjopen-2020-044036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689077/
https://www.ncbi.nlm.nih.gov/pubmed/33234662
http://dx.doi.org/10.1136/bmjopen-2020-044036

Ejemplares similares